PRNewsWire
16 Jun 2026, 20:44 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Neumora Therapeutics' navacaprant failed both the Phase 3 KOASTAL-2 and KOASTAL-3 trials for major depressive disorder. — Failure of two Phase 3 trials for a primary drug candidate represents a catastrophic loss of a potential commercial product.
-1.00Neumora Therapeutics announced an immediate workforce reduction of approximately 35%. — Large-scale layoffs immediately following clinical failures indicate severe operational distress and a pivot to survival mode.
-0.70Law firm Levi & Korsinsky has initiated an investigation into potential misleading statements by Neumora's officers regarding the navacaprant program. — Legal investigations and potential securities class actions introduce additional financial liability and reputational risk.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company reported failed Phase 3 trials for navacaprant and announced a 35% workforce reduction, causing the stock to fall nearly 50%.
The stock dropped sharply following a detailed short-seller report alleging irregularities.
The company is the subject of a securities fraud investigation after a stock price drop following an earnings call.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
1h ago
